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Mammographie screening after the age of 65 years: early outcomes in the 
Nijmegen programme
JAAM van Dijck1-2, ALM Verbeek1,2, JHCL Hendriks13, R Holland14 and M Mravunac5
'National Expert and Training Centre fo r  Breast Cancer Screening in the Netherlands, Departments o f 2Epidemiology, 3Radiology 
and 4Pathology, University o f  Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands; 5Department o f  Pathology, 
Canisius-Wilhelmina Hospital, PO Box 9015, NL-6500 GS Nijmegen, The Netherlands.
Summary We studied outcomes of mammographie screening in women older than 65 years. In 1975, breast 
cancer screening was started in Nijmegen, The Netherlands, for women aged 3 5 -6 5  years. Since 1977, 
approximately 7700 older women have also been invited for biennial one-view mammography. This report is 
based on ten screening rounds from 1975 to 1994. The results o f  the subsequent screening rounds in the age 
groups 6 5 -6 9  years, 70-74  years and 75 years and older were: participation rates 55%, 39% and 15%; screen- 
detected cancer rates 5.6%o, 6.9%o and 7.8%o; interval cancer rates 2.0%o, 1.8%o and 3.5%0; and predictive values 
o f  referral 62%, 64% and 62% respectively. In all age groups, screen-detected patients had smaller tumours 
and a lower prevalence o f  axillary lymph node involvement than unscreened patients. Our conclusion is that, in 
women aged 65 years and older, breast cancer can be detected at an earlier stage by mammographie screening.
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Breast cancer is the commonest malignancy in women. The 
incidence of invasive breast cancer in The Netherlands rises 
with age to about 340 new diagnosis annually per 100 000 
women aged 70 years and older (Netherlands Cancer 
Registry,. 1995). Approximately one out of three new cases 
o f invasive breast cancer is diagnosed in this age group. 
Although it has often been argued that this disease is more 
indolent in older women, their relative survival is no better 
than for younger women (Yancik et a l 1989).
Several trials have been conducted, and reviews of the 
results show that mammographic screening can reduce breast 
cancer mortality by approximately 30% (Fletcher et al., 1993; 
Nystrom et a l 1993; De Koning et al., 1995a). Recently, it 
was shown that mammographic screening of women aged 
6 5 -7 4  years can also reduce breast cancer mortality (Van 
Dijck et a l 1994, 1996; Chen et al., 1995).
To evaluate screening programmes that may have 
differently aged target populations, background material is 
necessary in order to assess the early results. For women aged 
5 0 -6 9  years, this information is available from several 
regional and national programmes (Peer et al., 1994; Tabar 
et al., 1993; De Koning et al., 1995b; Chamberlain et al., 
1993), but for older age groups, information is limited.
The aim of the present study was to determine age-specific 
outcomes of mammographic screening, with emphasis on 
women aged 65 years and older, in the Nijmegen programme, 
which is the only long-running trial in the world that 
included women over 75 years of age (Otten et al., 1996).
Study population and methods
In 1975, a population-based screening programme for breast 
cancer was started in Nijmegen, The Netherlands. In 1975 
and 1976, approximately 30 000 women aged 3 5 -6 5  years 
received their first invitation to participate in the mass 
mammographic screening. From the second round onwards, 
some 7700 older women were also invited for biennial one- 
view mammography. From 1975 up to 1994, ten screening 
rounds were carried out. Details of the programme and the
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round-specific results up to round 9 will be published 
elsewhere (Otten et al., 1996).
The present analyses concerned primary breast cancer 
patients diagnosed before December 1994. Excluded were 
patients with lobular carcinoma in situ, patients diagnosed 
before their first invitation to screening and women under the 
age of 50. Age, defined as the age on the date of invitation, was 
categorised as 5 0 -6 4 , 6 5 -6 9 , 7 0 -7 4  and 75 years and older.
The following indicators were studied for first and 
subsequent invitations separately: participation rate (i.e. 
number of accepted invitations per 100 invitations); referral 
rate (i.e. number o f referrals for diagnostic work-up per 1000 
accepted invitations); screen-detected cancer rate (i.e. number 
of screen-detected patients per 1000 accepted invitations); 
interval cancer rate (i.e. number o f patients diagnosed 
clinically after a negative screening result but before the 
next scheduled invitation 2 years later per 1000 accepted 
invitations); and the non-participant cancer rate (i.e. number 
of cancers diagnosed clinically in non-participants per 1000 
rejected invitations). The predictive value of referral (i.e. the 
number of diagnosed breast cancer patients per 100 referred 
women) and the ratio of screen-detected patients to screen- 
detected plus interval cancer patients were also calculated. 
Tumour size and lymph node status were studied according 
to the detection mode: (1) detected at first screening 
(including screen-detected patients who had rejected the 
invitation 2 years earlier); (2) detected at repeated screening 
(i.e. in women who had also participated in the previous 
round); (3) diagnosed clinically as an interval cancer; and (4) 
diagnosed clinically in non-participants (i.e. in women who 
had rejected the most recent invitation). Tumour size was 
measured in millimetres (mm) as the largest measurable size 
on the mammogram, or on the specimen radiography and 
histological slides if the tumour had vague margins or was 
radiographically occult. Axillary lymph node status was 
studied in patients diagnosed after 31 December 1980. 
Before this date, axillary lymph node dissection was not 
performed as a routine procedure and, as a result, the lymph 
node status was missing in 34% of the patients. From 1981 
onwards, the axillary lymph node status was missing in 10% 
of the patients.
The statistical tests used were the Kruskal Wallis test to 
analyse differences in median tumour size and the chi-square 
test for contingency tables to test differences in proportions. 
The analyses were performed with the statistical software 
package SAS.
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Results
Table I shows the number of invitations and the participation 
rates, referral rates and cancer rates for the first invitation. 
The participation rates for the first invitation decreased 
dramatically at older ages from 81% in women aged 5 0 -6 4  
years to 24% in women aged 75 years and older, while those 
for the subsequent invitations were some 10% lower at all 
ages. Table II shows corresponding details for subsequent 
invitations. The initial high rates of referral and detection 
(18% and 9%) dropped in the subsequent invitations to levels 
of about 10 and 6 per 1000 accepted invitations in women 
aged 65 years and older. The breast cancer detection rates in 
women who had been screened regularly (i.e. those also 
screened in the previous round) remained fairly high at 3.0, 
5.5, 6.0 and 6.3 per 1000 accepted invitations for the four age 
groups (not included in the tables). Interval cancer rates were 
slightly higher after subsequent invitations than after the first 
invitation. The non-participant cancer rates did not increase 
in the older age groups. The predictive value o f referral was
very high. At invitations, cancer was
diagnosed in two out of three referred women aged 65 and 
older. The ratio o f screen-detected cancers to the sum of 
screen-detected plus interval cancers was 0.69 or higher in 
women older than age 65.
Table III shows the tumour size o f invasive cancers, 
categorised as < 10  mm, 11-20  mm and > 2 0  mm, according 
to the detection mode and age. The median tumour sizes 
(with 25th and 75th centiles) are also presented. In each age 
group, the median size was smallest in the cancers detected at 
repeat screening and largest in non-participant cases Up­
values <0.001). The proportion of large tumours detected at 
first screening or those diagnosed in non-participants was 
somewhat larger in the oldest age groups (chi-square = 5.62, 
d.f. = 3, / > = 0.13; chi-square = 5.82, d.f. = 3, P —0.12), while 
the proportion of large interval cancers was slightly smaller in 
the oldest women (chi-square®55.17, d.f. = 3, P ~0 .16).
Table IV the node status of women
diagnosed between 1981 and 1994. Overall, the percentage 
‘unknown’ was 5%, 6%, 5% and 30% in the four age groups
Table I First invitations: screening results according to age at invitation
Age at invitation (years)
Screening result 5 0 - 6 4 65 -  69 7 0 -7 4 75 + Total
No. o f  invited women 13 149 2328 3122 4253 22 852
No. o f  participants 10 591 1440 1450 1009 14 490
Participation rate (% ) 81 62 46 24 63
Referrals
No. 158 22 27 20 227
Rate“ 14.9 15.3 18.6 19.8 15.7
Screen-detected cancers
No. 604 81 152 13' 968
Rate“ 5.7 5.6 10.3 12.9 6.6
Interval cancers
No. 17* 2' 3 2 242
Rate“ 1.6 1.4 2.1 2.0 1.7
Non-participant cancers
14' 35'No. 3 5 13
Rateb 5.5 3.4 3.0 4.0 4.2
Predictive value o f 38 36 56 65 42
referral (%)
Ratio screen-detected 0.78 0.80 0.83 0.87 0.80
to screen-detected
plus interval
Superscript denotes number of ductal carcinoma in situ included. “Per 1000 accepted invitations. ’ Per 1000 
rejected invitations.
Table II Subsequent invitations: screening results acc g to age at invitation
Age at invitation (years)
Screening result 50 04 65 69 70 -  74 75 + Total
....... -■ ............. : ......1 « i i*fi^ ‘ibi •••■.-, I-: •• ■ L‘ •• , s - t . i  .>■■■'■ • t < • f -  ■ s i ■ I >i s.-, t .
No. of invitations 98 851 28 398 2 1 079 33 949 182 277
No. of participations 66 073 15 708 81I6 5129 95 026
Participation rate (%) 67 55 39 15 52
Referrals
No. 401 143 87 65 696
Rate“ 6.1 9.1 10.7 12.7 7.3
Screen-detected cancers
888No. 22041 566 40s 404(’°
Rate“ 3.3 5.6 6.9 7.8 4.3
Interval cancers
18' 197*No. 1326 322 15
Rate" 2.0 2.0 1.8 3.5 2.1
Non-participant cancers
1073 122í 32910No. 51 49 2
Rateb 3.3 4.0 3.8 4.2 3.8
Predictive value of 55 62 64 62 58
referral (%)
Ratio screen-detected 0.63 0.73 0.79 0.69 0.67
to screen-detected
plus interval
Superscript denotes number of ductal carcinoma in situ included. 1 Per 1000 accepted invitations. hPer 1 
rejected invitations.
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(chi-square =  92.4, d.f. = 3, P < 0.001). Breast cancer-specific 
survival was poorest in patients with an unknown lymph 
node status; the 10 year breast cancer-specific survival rate 
was 0.40 for patients with unknown lymph node status, 
whereas it was 0.61 for patients with positive nodes and 0.92 
for patients with negative nodes. This illustrates the 
importance of considering all diagnosed patients instead of 
only those with a known lymph node status as the
In non-participants aged 75 years and older, the proportion 
of lymph node negatives was smaller than in the younger 
non-participants (34% and 47% respectively, P - 0.03).
Discussion
Mammographie screening can obviously only reduce the
denominator for the proportion of patients with negative mortality of breast cancer in the population if at least a
nodes. The proportion of lymph node-negative patients 
differed according to the detection mode (chi-square =  65.8, 
d.f. = 3, P <  0.001). In the patients detected at repeat 
screening it was 74%, while in non-participants it was 41%.
proportion of the invitees participates. The participation rates 
in women for the first invitation (65 -69  years, 81%; 70-74  
years, 67% and 51% for older women), declined for 
subsequent invitations (64% for ages 50 -69 , 39% for ages
Table III Tumour size of invasive cancers according to detection mode and age at invitation
Detection mode and 
tumour size 50 -  64
Age at invitation (years) 
6 5 - 6 9  7 0 -7 4 75 + Total
Detected at first screening“
<  10 mm 25 (28) 5 (29) 4 (16) 5 (21) 39 (25)
11 -20 mm 46 (51) 10 (59) 16 (64) 9 (38) 81 (52)
>  20 mm 19 (21) 2 (12) 5 (20) 10 (41) 36 (23)
Total 90 17 25 24 156
Median (2 5 -7 5  centile) 15 (10-20) 15 (10-15) 20 (1 5 -2 0 ) 20 (14 -27 ) 15 (11-20)
Detected at repeat screening
<  10 mm 57 (39) 27 (38) 14 (38) 11 (48) 109 (40)
10-20 mm 66 (46) 35 (49) 21 (55) 7 (30) 129 (47)
>20 mm 22 (13) 9 (13) 2 (6) 5 (22) 39 (14)
Total 145 71 37 23 2762
Median (2 5 -7 5  centile) 15 (10 -18 ) 15 (10 -20 ) 15 (1 0 -1 8 ) 12 (7 -2 0 ) 15 (10-20)
Diagnosed as interval cancer «
^  10 mm 19 (14) 3 (10) 4 (24) 4 (24) 30 (15)
10-20 mm 65 (46) 14 (45) 11 (65) 8 (47) 98 (48)
>  20 mm 56 (40) 14 (45) 2 (12) 5 (29) 77 (38)
Total 140 31 17’ 17 2055
Median (2 5 -7 5  centile) 20 (15-30) 20 (15 -30 ) 15 (15 -20 ) 20 (13 -25 ) 20 (15-30)
Diagnosed in non-participants
<  10 mm 12 ( 11) 4 ( 8 ) 2 (4 ) 5 (4) 23 (7)
11 -  20 mm 30 (28) 13 (27) 18 (35) 27 (23) 88 (27)
>  20 mm 66 (61) 32 (65) 31 (61) 88 (73) 217 (66)
Total 108 491 51' 120 328
Median (2 5 -7 5  centile) 25 (1 9 -3 5 ) 26 (20 -35 ) 25 (1 5 -3 5 ) 30 (20 -40 ) 30 (20-35)
Percentage between parenthesis. Superscript indicates the number of missing values. a Includes screen-detected patients who had rejected the 
previous screen invitation.
Table IV Axillary lymph node status of women diagnosed after 1980 according to detection mode and age at most recent
invitation
Detection mode and 
lymph nodes11 50 -  64
Age at invitation (years)
65 -  69 7 0 -  74 75 + Total
Detected at first screening" 
Negative1 22 (61) 7 (70) 13 (76) 6 (55) 48 (65)
Positive 13 (36) 3 (30) 3 (18) 3 (27) 22 (30)
N ot examined 1 (3) 0 (0) 1 (6) 2 (1 8 ) 4 (5)
Total 36 10 17 11 74
Detected at repeat screening
Negative 107 (78) 44 (69) 30 (77) 14 (64) 195 (74)
Positive 27 (20) 19 (30) 9 (23) 4 (18) 59 (23)
N ot examined 3 (2) 1 (2) 0 (0) 4 (1 8 ) 8 (3)
Total 137 64 39 22 262
Diagnosed as interval cancer
Negative 69 (63) 19 (66) 7 (50) 12 (67) 107 (63)
Positive 34 (31) 10 (34) 3 (21) 4 (22) 51 (30)
N ot examined 6 (6) 0 (0) 4 (29) 2 (11) 12(7)
Total 109 29 14 17 170
Diagnosed in non-participants
Negative 44 (46) 20 (48) 21 (47) 41 (34) 126 (42)
Positive 45 (47) 15 (36) 23 (51) 36 (30) 119 (39)
N ot examined 7 ( 7 ) 7 (1 7 ) 1 (2) 43 (36) 58 (19)
Total 96 42 45 120 303
a Includes screen-detected patients who had rejected the previous screen invitation. b Women with DCIS included as negative
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7 0 -74 , and 15% for older women); These rates were
disappointing with the two-county trial in
S w e d e n , in which, among women aged 70 -74  years, 72% 
participated after subsequent invitations (Arnesson et al.,
1995).
The effect of screening in the women who actually do 
participate may appear fairly large because the women who 
continue to participate have a longer life expectancy. In 
another study, we found a marked difference in survival of 
women who continued to participate at the age of 6 5 -6 6  
years compared with those who discontinued. The 10 year 
cumulative survival rates were 0.87 and 0.73 respectively (Van
. In Stockholm, similar results were
we reviewed the previous screening mammograms of 17 out 
of the 18 interval cancers. Two tumours (12%) had been 
missed at the previous screening examination; five tumours 
(29%) were visible in retrospect, but the signs were not
Dijck et al.,
specific enough for referral; and ten tumours (59%) had been 
radiographically occult at the previous screening. These 
findings are in agreement with the results of our study in 
1993 and do not provide an explanation for the high interval 
cancer rate (Van Dijck et al., 1993).
Two indicators of stage, i.e. tumour size and lymph node 
, were studied. In all age groups, screen-detected 
tumours were the smallest. Tumours detected at repeat 
screening had a median size of roughly 15 mm, whereas in 
non-participants the median size was 25-30  mm. In all agereported in participants and non-participants aged 4 0 -6 4  
years (Lidbrink et al., 1995). It is possible that participants groups there was a similar increase in the proportion of 
had fewer co-existing diseases or that these were less severe. patients with negative axillary nodes due to detection at 
There may even be an interaction between breast cancer and 
certain co-existing diseases. In breast cancer patients with 
localised or regional disease, Satariano and Ragland (1994) 
found that the probability o f survival decreased with an 
increasing number of co-existing conditions, whereas in 
patients with distant métastasés, the 3 year survival rate did
not depend on the number of other conditions. They 
concluded that women with severe co-existing diseases would 
not have a survival advantage because of early diagnosis.
One of the reasons for participation may be awareness of 
the presence of risk factors for breast cancer. If this is true, 
non-participants will be at less risk of breast cancer. The 
finding that the non-participant cancer rates did not increase 
with increasing age, in contrast to the screen-detected cancer 
rates and interval cancer rates, supports this hypothesis. In 
women over the age of 65, these non-participant cancer rates 
were approximately 2 per 1000 rejected invitations per 
annum, whereas the annual incidence of breast cancer in 
The Netherlands is about 3.5 per 1000 women (Netherlands 
Cancer Registry, 1995). In an earlier study, we also observed 
that the incidence of breast cancer in the non-participants 
was lower than would have been expected on the basis of a 
population without mass screening (Van Dijck et al., 1996). 
This means that one explanation for the high incidence in 
elderly participants, which was 4.5 per 1000 
subsequent invitations per annum at ages 65+ (calculated 
by the summation of screen-detected cancer and interval 
cancer rates in Table II), may be that the women who 
participate at a more advanced age are at greater risk for 
breast cancer. However, part of the increased incidence in 
participants may be artificial, because some of the detected 
cancers may never have become clinically detectable.
As breast cancer incidence increases with increasing age, it
was expected that screen-dctc' cancer rates and interval
cancer rales would also show the same pattern. Owing to the 
slower growth rate (Peer et al., 1993), it was expected that the
ratio of screen-detected to screen-detected plus interval
increasing age. In the 75 + 
the proportion o f interval cancers was 
relatively high. In order to find an explanation for this result,
repeat screening vs clinical detection in non-participants. 
Thus, it may be concluded that, through periodic screening 
with mammography in women over the age of 65, breast 
cancer can be detected at a similar early stage as in those 
aged 50-64  years.
In summary, our data show that, in women aged 65 years 
and older, breast cancer can be diagnosed at an earlier stage 
by mammographic screening. This does not imply that the 
life expectancy of all screen-detected patients will be longer. 
First, a larger proportion of the screen-detected cancers may 
have remained undiagnosed without screening because of the 
slow growth rate (Peer et al., 1993). Second, women of 75 
have a life expectancy of 11 years and those of 85 of 6 years 
(Wegman, 1993). The duration of the detectable preclinical 
phase in women aged 70 years and older has been estimated 
at 4.5 years (Peer et al, 1996). It is thus unlikely that many 
breast cancer deaths can be prevented in patients screened at 
age 75 years and older, but the quality of life may be 
increased if screening can prevent them from having to live 
for years with metastases.
We conclude that there is reason to continue mammo­
graphic screening until at least the age of 75 years. The 
beneficial of mammographic screening on
cancer mortality and the quality of life may outweigh the 
negative side-effects until the age when life expectancy is 
shorter than the detectable preclinical phase of the disease.
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